echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Natural Products News > GeroScience: Scientists identify new mechanisms of action for special drugs that fight Alzheimer's disease!

    GeroScience: Scientists identify new mechanisms of action for special drugs that fight Alzheimer's disease!

    • Last Update: 2021-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    JANUARY 4, 2021 // -- In a recent study published in the international journal GeroScience, scientists from the University of Barcelona and other institutions identified a mechanism for the role of a potential compound against Alzheimer's disease in mice.
    This new drug belongs to a family of molecules that, when combined with the Mide I2 subject, promotes a decrease in neuro-inflammatory levels, improvements in the body's cognitive function, and improvements in other markers of disease progression, which are most common in people with dementia.
    Photo Source: Pixabay/CC0 Public Domain, a new compound with high affinity and selectivity to Midean I2 subjects, was designed and synthesized by researcher Carmen Escolano and is present in multiple organs and involved in a variety of body physiology processes, including analgesics, inflammation, and neurological disorders.
    , it is also associated with the progression of neurodegeneration and appears to increase in the brains of Alzheimer's patients.
    In previous studies, researchers have revealed the positive effects of these compounds on the evolution and progression of Alzheimer's disease, and based on previous research, the researchers aim to determine the mechanisms and parameters that change when drugs are used in animal models, especially in aging-related neurodegenerative mice, which are thought to be associated with the onset of late-onset Alzheimer's disease, meaning that symptoms of the disease begin at age 65. In the
    study, researchers analyzed different biomarkers in the course of disease progression, as well as short- and long-term behavioral and memory test results in mice, to study the effects of therapy on mouse body behavior and memory, and found that when mice received the new drug, their body symptoms improved significantly compared to the control group.
    The new molecule improves cognitive function in mice and reduces their anxiety symptoms, and the researchers have also confirmed at the molecular level that treatment based on this molecule may reduce typical neuroinstatic and oxidative stress in alzheimer's patients, while also reducing levels of pathological markers such as tau protein or β amyloid. the
    -related findings may help researchers analyze the mechanism of effect of the new compound, while also providing evidence that molecular changes that occur after the treatment may be related to calcineurin pathways, which are responsible for the production of inflammatory mediated factors such as cytokines and the reduction of neuroplasticity.
    the researchers say the findings may open up new possibilities for studies of the families of mitropod I2 mediators, as the results of cognitive improvements in neurodegenerative animal models depend on the mechanisms by which they work.
    () Original source: Foteini Vasilopoulou et al, I2 imidazoline receptor modulation protects aged SAMP8 mice againstst the cognitive decline by suppressing the calcineurin pathway, GeroScience (2020). DOI:10.1007/s11357-020-00281-2。
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.